I am really looking forward to seeing more results from this trial. Something SI said has me intrigued:
"the companies are working closely together to complete analysis of a variety of secondary endpoints, including days in intensive care, other end-organ damage (potentially recovery), and measurement of circulating cytokines and biomarkers."
I added the parentheses; didn't include them in the transcript. But the way SI said this makes me think they belong there - that he was telling us we might see some recovery of "other end organ damage" following treatment with Remestemcel-L.
GLTAH!
Ann: COVID ARDS Trial Topline 60-Day Results, page-1389
-
- There are more pages in this discussion • 240 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.46 |
Change
0.015(1.04%) |
Mkt cap ! $1.661B | |||
| Open | High | Low | Value | Volume |
| $1.44 | $1.46 | $1.40 | $3.815M | 2.664M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 11031 | $1.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 14844 | 2 |
View Market Depth
| Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |